Annual Cash & Cash Equivalents
$14.88 M
+$6.17 M+70.82%
December 31, 2023
Summary
- As of February 8, 2025, EFTR annual cash & cash equivalents is $14.88 million, with the most recent change of +$6.17 million (+70.82%) on December 31, 2023.
- During the last 3 years, EFTR annual cash & cash equivalents has fallen by -$341.00 thousand (-2.24%).
- EFTR annual cash & cash equivalents is now -70.07% below its all-time high of $49.70 million, reached on December 31, 2021.
Performance
EFTR Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$15.51 M
+$633.00 K+4.26%
March 31, 2024
Summary
- As of February 8, 2025, EFTR quarterly cash and cash equivalents is $15.51 million, with the most recent change of +$633.00 thousand (+4.26%) on March 31, 2024.
- Over the past year, EFTR quarterly cash and cash equivalents has increased by +$5.20 million (+50.42%).
- EFTR quarterly cash and cash equivalents is now -71.68% below its all-time high of $54.77 million, reached on September 30, 2021.
Performance
EFTR Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
EFTR Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +70.8% | +50.4% |
| 3 y3 years | -2.2% | +50.4% |
| 5 y5 years | -2.2% | +50.4% |
EFTR Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -70.1% | +70.8% | -68.8% | +187.9% |
| 5 y | 5-year | -70.1% | +70.8% | -71.7% | +187.9% |
| alltime | all time | -70.1% | +70.8% | -71.7% | +187.9% |
EFFECTOR Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2024 | - | $15.51 M(+4.3%) |
| Dec 2023 | $14.88 M(+70.8%) | $14.88 M(+176.2%) |
| Sep 2023 | - | $5.39 M(-63.4%) |
| Jun 2023 | - | $14.71 M(+42.7%) |
| Mar 2023 | - | $10.31 M(+18.4%) |
| Dec 2022 | $8.71 M | $8.71 M(-26.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $11.90 M(-27.2%) |
| Jun 2022 | - | $16.35 M(-7.4%) |
| Mar 2022 | - | $17.66 M(-64.5%) |
| Dec 2021 | $49.70 M(+226.6%) | $49.70 M(-9.2%) |
| Sep 2021 | - | $54.77 M(+259.9%) |
| Dec 2020 | $15.22 M | $15.22 M |
FAQ
- What is eFFECTOR Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for eFFECTOR Therapeutics?
- What is eFFECTOR Therapeutics annual cash & cash equivalents year-on-year change?
- What is eFFECTOR Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for eFFECTOR Therapeutics?
- What is eFFECTOR Therapeutics quarterly cash and cash equivalents year-on-year change?
What is eFFECTOR Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of EFTR is $14.88 M
What is the all time high annual cash & cash equivalents for eFFECTOR Therapeutics?
eFFECTOR Therapeutics all-time high annual cash & cash equivalents is $49.70 M
What is eFFECTOR Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, EFTR annual cash & cash equivalents has changed by +$6.17 M (+70.82%)
What is eFFECTOR Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of EFTR is $15.51 M
What is the all time high quarterly cash and cash equivalents for eFFECTOR Therapeutics?
eFFECTOR Therapeutics all-time high quarterly cash and cash equivalents is $54.77 M
What is eFFECTOR Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, EFTR quarterly cash and cash equivalents has changed by +$5.20 M (+50.42%)